<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

S. Karapetis, Christos; Khambata‐Ford, Shirin; J. Jonker, Derek; J. O’Callaghan, Chris; Tu, Dongsheng; C. Tebbutt, Niall; J. Simes, R.; Chalchal, Haji; Shapiro, Jeremy; Robitaille, Sonia; Price, Timothy; E. Shepherd, Lois; Au, Heather‐Jane; Langer, Christiane; J. Moore, Malcolm; Zalcberg, John

doi:10.1056/nejmoa0804385

Public

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Published in New England Journal of Medicine • Oct 22, 2008

Authors:

Christos S. Karapetis

Shirin Khambata‐Ford

Derek J. Jonker

Abstract

BACKGROUND: Treatment with cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, improves overall and progression-free survival and preserves the quality of life in patients with colorectal cancer that has not responded to chemotherapy. The mutation status of the K-...

Subject

Cetuximab

Medicine

Colorectal cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!